LLPi:Liverpool Lung Project risk prediction model for lung cancer incidence

Cancer Prevention Research

Volumn 8, Issue 6, 2015, Pages 570-575

  Marcus, Michael W ^a   Chen, Ying ^a   Raji, Olaide Y ^a   Duffy, Stephen W ^b   Field, John K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CALIBRATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HUMAN; LIVERPOOL LUNG PROJECT RISK PREDICTION MODEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING; CLINICAL TRIAL (TOPIC); FOLLOW UP; GREAT BRITAIN; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; SURVIVAL RATE;

AGED; CLINICAL TRIALS AS TOPIC; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84941790075     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0438     Document Type: Article

References (51)

1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
2. Qi WX, Wang Q, Jiang YL, Sun YJ, Tang LN, He AN, et al. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. PLoS One 2013;8:e55637.
3. National Lung Screening Trial Research T Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
4. Cassidy A, Duffy SW, Myles JP, Liloglou T, Field JK. Lung cancer risk prediction: a tool for early detection. Int J Cancer 2007;120:1-6.
5. Field JK. Lung cancer risk models come of age. Cancer Prev Res 2008;1:226-8.
6. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-26.
7. Etzel CJ, Kachroo S, Liu M, D'Amelio A, Dong Q, Cote ML, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res 2008;1:255-65.
8. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-6.
9. Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, et al. An expanded risk prediction model for lung cancer. Cancer Prev Res 2008;1:250-4.
10. Miettinen OS. Matching and design efficiency in retrospective studies. Am J Epidemiol 1970;91:111-8.
11. Breslow NE, Day NE. Statistical methodsincancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980:5-338.
12. Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet 2002;359:431-4.
13. Vandenbroucke JP, Pearce N. Case-control studies: basic concepts. Int J Epidemiol 2012;41:1480-9.
14. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002;359:341-5.
15. Mann CJ. Observationalresearchmethods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J 2003;20:54-60.
16. Raji OY, Duffy SW, Agbaje OF, Baker SG, Christiani DC, Cassidy A, et al. Predictive accuracy of the Liverpool Lung Project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann Intern Med 2012;157:242-50.
17. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PloS one 2011;6:e17479.
18. Field JK, Smith DL, Duffy S, Cassidy A. The Liverpool Lung Project research protocol. Int J oncol 2005;27:1633-45.
19. Clarke LC, Fraser SG. Hospital Episode Statistics and trends in ophthalmic surgery 1998-2004. BMC Ophthalmol 2006;4:37.
20. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
21. Therneau TM, Grambsch PM. Martingale-based residuals for survival models. Biometrika 1990;77:147-60.
22. Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 1996;49:907-16.
23. Moons KG, Kengne AP, Woodward M, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio) marker. Heart 2012;98:683-90.
24. Harrell FE, Califf RM, Prvor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247; 2543-6.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
26. Efron B. Bootstrap methods: another look at the jackknife. Ann. Statist 1979;7:1-26.
27. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-81.
28. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
29. Loughin TM, Koehler KJ. Bootstrapping regression parameters in multivariate survival analysis. Lifetime Data Anal 1997;3:157-77.
30. Schumacher M, Hollander N, Sauerbrei W. Resampling and cross-validation techniques: a tool to reduce bias caused by model building? Stat Med 1997;16:2813-27.
31. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8.
32. Cronin KA, Gail MH, Zou Z, Bach PB, Virtamo J, Albanes D. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst 2006;98:637-40.
33. D'Amello AM Jr, Cassidy A, Asomaning K, Raji OY, Duffy SW, Field JK, et al. Comparisonofdiscriminatory power and accuracyofthree lung cancer risk models. Br J Cancer 2010;103:423-9.
34. Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011;103:1058-68.
35. Park S, Nam B-H, Yang H-R, Lee JA, Lim H, Han TJ, et al. Individualizedrisk prediction model for lung cancer in Koran men. Plos One 2013;8:e54823.
36. Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Ostergaard JN, et al. A risk model for lung cancer incidence. Cancer Prev Res 2012;5:834-46.
37. Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36.
38. Whittemore AS. Evaluating health risk models. Stat Med 2010;29:2438-52.
39. Brenner DR, Boffetta P, Duell EJ, Bickeboller H, Rosenberger A, McCormack V, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol 2012;176:573-85.
40. Rosenberger A, Bickeboller H, McCormack V, Brenner DR, Duell EJ, Tjonneland A, et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. Carcinogenesis 2012;33:587-97.
41. Field JK, Chen Y, Marcus MW, McRonald FE, Raji OY, Duffy SW. The contribution of risk prediction models to early detection of lung cancer. J Surg Oncol 2013;108:304-11.
42. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7.
43. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22.
44. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42.
45. Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC cancer 2010;10:600.
46. Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res 2012;72:5692-701.
47. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013;31:4140-7.
48. Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. B J Cancer 2010;103:1144-8.
49. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, et al. Plasma microRNAs as novel biomarkers for early detectionof lung cancer. Int J Clin Exp Pathol 2011;4:575-86.
50. Hennessey PT, Sanford T, Choudhary A, Mydlarz WW, Brown D, Adai AT, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PloS one 2012;7:e32307.
51. Bediaga NG, Davies MP, Acha-Sagredo A, Hyde R, Raji OY, Page R, et al. A microRNA-based prediction algorithm for diagnosisofnon-small lung cell carcinoma in minimal biopsy material. B J Cancer 2013;109:2404-11.